Clinical trial platform for new drugs
The platform helps to promote and integrate clinical trial for new drugs and continue the result from various technology platforms in the R&D center. It also masters all the techniques required for the development stage of various new drugs and follows the domestic and foreign regulations.
Project management monitors the progress of the trials and improves efficiency. It also caters to the safety of test subject and legal regulation, accelerating the industrialization and commercialization of trial result.
Immunocyte image calibration
With the rapid development in cellular biology and molecular biology technology, the number of researches on technology that uses magnetic nanoparticles for cell labeling has been increasing. The contrast agent is first used to label cells. After the cells have been transplanted into the body, MRI can be used to track the distribution, movement, and location of the cells. This enables the scientists and doctors to track and understand the safety and movement of cells after the transplant. Currently, the MRI contrast agent developed by MegaPro Biomedical can be used to label immunocytes including T-lymphocyte, macrophage and dendritic cell. Due to the effect of phagocytosis, this can be done in vitro or through direct injection of contrast agent into the body. The higher phagocytic activity of this type of phagocytic cells can be used for labeling (Figure 1).
Figure 1：Light microscopy of cells labeled with ITRI-IOP. Light microscopy of a macrophages, b dendritic cells, and c MSCs cocultured with ITRI-IOP for 24 h.
After the cells have been labeled with nanoparticles, high-resolution NMRI instrument can be used to track the movement of cells in vivo. This provides scientists with insights on various immunoreactions including the activation and reaction process of macrophages during tissue transplant rejection. It can also be used to track autoimmune disease and movement of cancer cells in the lymph nodes during metastasis. These applications aid in disease diagnosis, allowing doctors to provide timely treatment (Figure 2).
Figure 2：Using a non-invasive method to tract macrophages in vivo during tissue transplant rejection.
新竹縣竹東鎮中興路四段 195 號 52 館 526 室 工業技術研究院 中興院區 創業育成中心 ©巨生生醫股份有限公司
Suite 526, Bldg.52, No.195, Sec.4, Chung Hsing Rd., Chutung, Hsinchu, 31040, Taiwan, R.O.C.
Tel: +866-3-591-0360 Fax:+886-3-591-0441
©MegaPro Biomedical Co., Ltd. Copyright ｜ Contact us